Fol. Biol. 2021, 67, 126-133
https://doi.org/10.14712/fb2021067030126
Luteoloside Ameliorates Palmitic Acid-Induced in Vitro Model of Non-alcoholic Fatty Liver Disease via Activating STAT3-Triggered Hepatocyte Regeneration
Crossref Cited-by Linking
- Yang Bing, Li Xiaofeng: Epigenetic Regulation of Manganese\u2010Induced Hepatotoxicity Uncovering Histone Demethylation\u2010Associated Gene Networks. J Biochem & Molecular Tox 2025, 39. <https://doi.org/10.1002/jbt.70556>
- Cen Chenyi, Li Jiahuan, Zhou Pu, Fisher David, Hien Nguyen Thi Thu, Musabaev Erkin, Pronyuk Khrystyna, Zhao Lei: The effects of cynaroside on lipid metabolism and lipid-related diseases: a mechanistic overview. Front. Pharmacol. 2025, 16. <https://doi.org/10.3389/fphar.2025.1648614>
- Shu Yongsheng, Shen Wanqing, Feng Wanyu, Pan Meijun, Xu Xinyi, Zheng Shuguo, Jin Huanhuan: Targeting HMGCS2: Ketogenesis Suppression Accelerates NAFLD Progression in T2DM Comorbidity, While Cynaroside Ameliorates NASH in Concomitant T2DM. Biomolecules 2025, 15, 1181. <https://doi.org/10.3390/biom15081181>
- Xiu Mengxue, Zhao Yiming, Wang Xuehui, Yuan Siyu, Qin Bofeng, Sun Jinghui, Cui Long, Song Jian: Regulation of SIRT1-TLR2/TLR4 pathway in cell communication from macrophages to hepatic stellate cells contribute to alleviates hepatic fibrosis by Luteoloside. Acta Histochemica 2023, 125, 151989. <https://doi.org/10.1016/j.acthis.2022.151989>
- Wang Lu, Yan Yonghuan, Wu Linfang, Peng Jinyong: Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development. Pharmacological Research 2023, 196, 106925. <https://doi.org/10.1016/j.phrs.2023.106925>
